Status:
TERMINATED
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
Lead Sponsor:
University of Louisville
Collaborating Sponsors:
James Graham Brown Cancer Center
Novartis Pharmaceuticals
Conditions:
Carcinoma, Non-Small Cell Lung
Carcinoma, Small Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.
Detailed Description
The purpose of this research study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases. The blood test will look for a protein, called TRAP, which is re...
Eligibility Criteria
Inclusion
- invasive lung cancer (small cell or non-small cell lung cancer)
- osteolytic bone metastasis determined by clinical exam, bone scan/XR
- age \> 18 years
Exclusion
- concurrent malignancy with a second primary
- renal failure (serum creatinine \> 3mg/dl)
- pregnancy
- active rheumatoid arthritis
- intolerance to zoledronic acid
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00265200
Start Date
February 1 2005
End Date
December 1 2010
Last Update
March 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
James Graham Brown Cancer Center
Louisville, Kentucky, United States, 40202